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Abstract
Background: Pulmonary arterial hypertension (PAH) is a rare disease characterized by distinctive changes in
pulmonary arterioles that lead to progressive pulmonary arterial pressures, right-sided heart failure, and a high
mortality rate. Up to 30% of adult and 75% of pediatric PAH cases are associated with congenital heart disease
(PAH-CHD), and the underlying etiology is largely unknown. There are no known major risk genes for PAH-CHD.
Methods: To identify novel genetic causes of PAH-CHD, we performed whole exome sequencing in 256 PAH-CHD
patients. We performed a case-control gene-based association test of rare deleterious variants using 7509 gnomAD
whole genome sequencing population controls. We then screened a separate cohort of 413 idiopathic and familial
PAH patients without CHD for rare deleterious variants in the top association gene.
Results: We identified SOX17 as a novel candidate risk gene (p = 5.5e−7). SOX17 is highly constrained and encodes
a transcription factor involved in Wnt/β-catenin and Notch signaling during development. We estimate that rare
deleterious variants contribute to approximately 3.2% of PAH-CHD cases. The coding variants identified include
likely gene-disrupting (LGD) and deleterious missense, with most of the missense variants occurring in a highly
conserved HMG-box protein domain. We further observed an enrichment of rare deleterious variants in putative
targets of SOX17, many of which are highly expressed in developing heart and pulmonary vasculature. In the
cohort of PAH without CHD, rare deleterious variants of SOX17 were observed in 0.7% of cases.
Conclusions: These data strongly implicate SOX17 as a new risk gene contributing to PAH-CHD as well as idiopathic/
familial PAH. Replication in other PAH cohorts and further characterization of the clinical phenotype will be important
to confirm the precise role of SOX17 and better estimate the contribution of genes regulated by SOX17.
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Background
Pulmonary arterial hypertension (PAH[MIM:178600]) is a
rare disease characterized by distinctive changes in pulmon-
ary arterioles that lead to progressive pulmonary arterial
pressures, right-sided heart failure and a high mortality rate.
Up to 30% of adult- [1, 2] and 75% of pediatric-onset PAH
cases [3] are associated with congenital heart disease
(PAH-CHD), and due to improved treatments, the number
of adults with PAH-CHD is rising [1, 4]. Congenital heart de-
fects can result in left-to-right (systemic-to-pulmonary)
shunts leading to increased pulmonary blood flow and risk
of PAH. However, not all patients are exposed to prolonged
periods of increased pulmonary flow. PAH may persist
following surgical repair of cardiac defects or recur many
years after repair. Thus, the underlying etiology is heteroge-
neous and may include increased pulmonary blood flow,
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pulmonary vasculature abnormalities, or a combination. In
addition to environmental factors, genetic factors likely play
an important role in PAH-CHD although no major risk gene
has been identified to date [1].
Genetic studies of PAH alone have identified 11
known risk genes for PAH [5–8]. Several of the risk
genes encode members of the transforming growth fac-
tor beta/bone morphogenetic protein (TGF-β/BMP) sig-
naling pathway, important in both vasculogenesis and
embryonic heart development. For example, mutations
in bone morphogenetic protein receptor type 2 (BMPR2)
are found in approximately 70% of familial and 10–40%
of idiopathic PAH cases. Estimates of the frequency of
BMPR2 mutations in PAH-CHD are considerably lower
than for PAH alone [9–11]. Mutations in other TGFβ
family member genes—activin A, receptor type II-like 1
(ACVRL1), endoglin (ENG), BMP receptor type 1A
(BMPR1A) and type 1B (BMPR1B)—as well as caveolin-1
(CAV1), eukaryotic initiation translation factor 2 alpha
kinase 4 (EIF2AK4), potassium two-pore-domain channel
subfamily K member 3 (KCNK3), SMAD family members
4 and 9 (SMAD4 and SMAD9), and T-box4 (TBX4) have
all been identified as less frequent or rare causes of PAH
[5–8]. The genetics of CHD are complex and no single
major risk gene accounts for more than 1% of cases
[12, 13]. Aneuploidies and copy number variations
underlie up to 23% of CHD cases [14, 15]. Rare, inherited,
and de novo variants in hundreds of genes encoding tran-
scription factors, chromatin regulators, signal transduc-
tion proteins, and cardiac structural proteins have been
implicated in ~ 10% of CHD cases [12, 16–19].
To identify novel genetic causes of PAH-CHD, we per-
formed exome sequencing in a patient cohort of
PAH-CHD. Association analysis using population con-
trols identified SOX17, a member of the SRY-related
HMG-box family of transcription factors, as a new can-
didate risk gene.
Methods
An overview of the experimental design and workflow is
provided in Additional file 1: Figure S1.
Patients
PAH-CHD patients were recruited from the pulmonary
hypertension centers at Columbia University and Chil-
dren’s Hospital of Colorado (via enrollment in the PAH
Biobank at Cincinnati Children's Hospital Medical Cen-
ter). Patients were diagnosed according to the World
Health Organization (WHO) pulmonary hypertension
group I classification [20]. The diagnosis of PAH-CHD
was confirmed by medical record review including right
heart catheterization and echocardiogram to define the
cardiac anatomy. The cohort included 15 familial cases,
160 singletons with no family history of PAH, 61 trios
(proband and two unaffected biological parents), and 20
duos (proband and one unaffected parent). Written in-
formed consent (and assent when appropriate) was ob-
tained under a protocol approved by the institutional
review board at Columbia University Medical Center or
Children’s Hospital of Colorado.
Whole exome sequencing (WES)
Familial cases were screened for BMPR2 and ACVRL1muta-
tions by Sanger sequencing and multiplex ligation-dependent
probe amplification (MLPA). Familial cases without muta-
tions in the two risk genes and all other samples were exome
sequenced. DNA was extracted from peripheral blood
leukocytes using Puregene reagents (Gentra Systems Inc.,
Minnesota, USA). Exome sequencing was performed in col-
laboration with the Regeneron Genetics Center (RGC) or at
the Children’s Hospital of Cincinnati. In brief, genomic DNA
processed at the RGC was prepared with a customized
reagent kit from Kapa Biosystems and captured using the
SeqCap VCRome 2 exome capture reagent or xGen lock-
down probes. Patient DNA samples sequenced at the PAH
Biobank/Cincinnati Children’s Hospital Medical Center were
prepared with the Clontech Advantage II kit and enriched
using the SeqCap EZ exome V2 capture reagent. All samples
were sequenced on the Illumina HiSeq 2500 platform,
generating 76-bp paired-end reads. Read-depth cover-
age was ≥ 15× in ≥ 95% of targeted regions for all ex-
ome sequencing samples.
WES data analysis
The workflow is outlined in Additional file 1: Figure S1A.
We used a previously established bioinformatics procedure
[18] to process and analyze exome sequence data. Specific-
ally, we used BWA-MEM (Burrows-Wheeler Aligner) [21]
to map and align paired-end reads to the human reference
genome (version GRCh37/hg19), Picard MarkDuplicates to
identify and flag PCR duplicate reads, GATK HaplotypeCal-
ler (version 3) [22, 23] to call genetic variants, and GATK
variant quality score recalibration (VQSR) to estimate ac-
curacy of variant calls. We used heuristic filters to minimize
potential technical artifacts, excluding variants that met any
of the following conditions: missingness > 10%, minimum
read depth ≤ 8 reads, allele balance ≤ 20% [24], genotype
quality < 30, mappability < 1 (based on 150 bp fragments),
or GATK VQSR < 99.6. Only variants with FILTER “PASS”
in gnomAD WGS and restricted to the captured protein
coding region were kept.
We used ANNOVAR [25] to annotate the variants and
aggregate information about allele frequencies (AF) and in
silico predictions of deleteriousness. We used population AF
from public databases: Exome Aggregation Consortium
(ExAC) [26] and Genome Aggregation Database (gnomAD).
Rare variants were defined by AF < 0.01% in both ExAC and
gnomAD WES datasets. We employed multiple in silico
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prediction algorithms including PolyPhen 2, metaSVM [27],
Combined Annotation Dependent Depletion (CADD) [28],
and REVEL (rare exome variant ensemble learner) [29]. We
noted that REVEL outperformed other ensemble methods
in pathogenicity prediction in a recent comparison using
clinical genetic data [30]. We performed further evaluation
of the prediction toolkits using de novo missense variants
published in a recent CHD study [19] and published de
novo variants of unaffected siblings of Simons Simplex Col-
lection [31] as controls. We observed that REVEL-predicted
damaging missense de novo variants reached the highest en-
richment rate in cases compared to controls (Additional file 1:
Figure S1B). Thus, we ultimately used REVEL to define dam-
aging missense variants (D-mis, REVEL > 0.5) in this study.
We identified de novo variants in a set of 60 PAH-CHD
trios using methods described previously [18, 32], and
manually inspected all candidate de novo variants using
the Integrative Genomics Viewer (IGV) [33] to exclude
potential false positives.
Identification of rare, deleterious variants in established
risk genes
We screened for variants in 11 known risk genes for PAH
[5–8]: ACVRL1, BMPR1A, BMPR1B, BMPR2, CAV1,
EIF2AK4, ENG, KCNK3, SMAD4, SMAD9, and TBX4. We
also screened for variants in the recently curated list of
253 candidate risk genes for CHD [19]. Variants identified
in the PAH-CHD cohort were compared to mutations re-
ported in the literature and in genetic databases (Online
Mendelian Inheritance in Man database, Human Genome
Mutation Database [34] and ClinVar [35]). We defined
deleterious variants as likely gene-disrupting (LGD) (in-
cluding premature stopgain, frameshift indels, canonical
splicing variants, and deletion of exons) or damaging mis-
sense with REVEL score > 0.5 (D-mis). Insertion/deletion
variants in known risk genes were confirmed with Sanger
sequencing and tested for disease segregation when family
DNA samples were available.
Statistical analysis
To identify novel candidate risk genes, we performed a
case-control association test comparing frequency of
rare deleterious variants in each gene in PAH-CHD
cases with gnomAD whole genome sequencing (WGS)
subjects as population controls. To control for ethnicity,
we selected cases of European ancestry (n = 144) using
principal components analysis (PCA) (Peddy software
package) [36] (Additional file 1: Figure S1C) and gno-
mAD subjects of non-Finnish European (NFE) ancestry
(n = 7509). Since cases and controls were sequenced
using different platforms, we assessed the batch effect
based on the burden of rare synonymous variants, a vari-
ant class that is mostly neutral with respect to disease
status. We observed that the frequency of rare
synonymous variants in cases and controls was virtually
identical (enrichment rate = 1.01, p value = 0.4) (Add-
itional file 1: Table S3a). The analysis of
disease-associated genes was confined to gene-specific
enrichment of rare, deleterious variants (AF < 0.01%,
LGD or D-mis). We assumed that under the null model,
the number of rare deleterious variants observed in cases
should follow a binomial distribution, given the total
number of such variants in cases and controls, and a rate
determined by fraction of cases in total number of sub-
jects (cases and controls). The enrichment rate was then
determined by the average number of variants in cases
over the sum of average number of variants in cases and
controls. The statistical significance of enrichment was
tested using binom.test in R. We defined the threshold
for genome-wide significance by Bonferroni correction
for multiple testing (n = 17,701, threshold p value = 2.8e
−6). We used the Benjamini-Hochberg procedure to es-
timate false discovery rate (FDR) by p.adjust in R. All
SOX17 variants reported herein were confirmed with
Sanger sequencing and inheritance determined when
parental DNA samples were available.
To guard against spurious association results due to
population differences or batch effects inherent to the
use of publicly available gnomAD data, we repeated the
association analysis using a set of 1319 European control
subjects with individual level data obtained from the
same analytical pipeline and called jointly with the
PAH-CHD cases. These controls were comprised of un-
related, unaffected European parents from the Pediatric
Cardiac Genomics Consortium [18]. The data were captured
using NimbleGen V2.0. We performed principle compo-
nents analysis of ethnicity with cases and controls together.
To estimate the burden of de novo variants in cases,
we calculated the background mutation rate using a pre-
viously published tri-nucleotide change table [32, 37]
and calculated the rate in protein-coding regions that
are uniquely mappable. We assumed that the number of
de novo variants of various types (e.g., synonymous, mis-
sense, LGD) expected by chance in gene sets or all genes
followed a Poisson distribution [32]. For a given type of
de novo variant in a gene set, we set the observed num-
ber of cases to m1, the expected number to m0, esti-
mated the enrichment rate by (m1/m0), and tested for
significance using an exact Poisson test (poisson.test in
R) with m0 as the expectation.
Results
Characteristics of the PAH-CHD cohort are shown in
Table 1. The cohort included 15 familial and 241 sporadic
cases, including 61 parent-child trios and 20 duos. The
majority of cases (56%) had an age of PAH onset < 18 years
(pediatric-onset). There were more females among both
pediatric-onset (n = 91/53, 1.7:1 female-to-male ratio)
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and adult-onset (n = 88/24, 3.7:1) patients, with a sig-
nificant ~ 2-fold enrichment of females for adult- com-
pared to pediatric-onset PAH (p = 0.009) (Table 1).
Fifty-six percent of the patients were of European an-
cestry, 26% Hispanic, and 5–7% each of African, East
Asian, or South Asian. The most common cardiac de-
fects were atrial and ventricular septum defects; how-
ever, more severe defects were more frequent in
pediatric-onset cases.
Rare deleterious variants in known PAH and CHD risk
genes
We screened for rare, predicted deleterious variants in
11 known risk genes for PAH and 253 candidate risk
genes for CHD (Additional file 1: Table S1). PAH risk
gene variants were identified in only 6.4% (16/250) of
sporadic PAH-CHD cases and four of 15 familial cases
(Additional file 1: Table S2). Of these cases, the majority
had pediatric-onset disease (17/144 pediatric vs 3/112
adult, p = 0.0085 Fisher’s exact test). Most of the rare
deleterious variants were identified in BMPR2 (n = 7, 6
pediatric) and TBX4 (n = 7, all pediatric) with a few vari-
ants in BMPR1A (n=1), BMPR1B (1), CAV1 (1), ENG
(1), and SMAD9 (2). Parental DNA samples were available
for a subset of the cases and three TBX4 variants were
confirmed to be de novo: c.C293G:p.P98R,
c.537_546del:p.1801 fs*45, and c.669_671del:p.223_224delF.
We performed enrichment analysis for the PAH gene set in
all PAH-CHD individuals of European ancestry (n = 143),
using NFE gnomAD WGS subjects (n = 7509) as popula-
tion controls. Similar frequencies of synonymous variants
in cases and controls indicated that potential batch effects
were minimal between the two independent datasets (Add-
itional file 1: Table S3a). For the known PAH gene set, we
observed a 5.7-fold enrichment of rare deleterious (LGD or
D-mis) variants in PAH-CHD (P = 0.001) (Add-
itional file 1: Table S3b). In contrast, there was no en-
richment of rare deleterious variants in CHD risk genes
in cases compared to controls (Additional file 1: Table
S3b; Additional file 2: Table S4), indicating that overall
these variants contribute little to PAH-CHD risk.
Association analysis identifies transcription factor SOX17
as a new candidate PAH-CHD risk gene
To identify novel risk genes for PAH-CHD, we performed
an association analysis comparing per-gene rate of rare
deleterious variants in European cases and NFE gnomAD
WGS controls. We used a binomial test to assess the
significance in 17,701 genes and found SOX17 to be
associated with PAH-CHD with genome-wide significance
(5/143, 3.3% of cases vs 5/7509, 0.07% of controls; enrich-
ment rate = 52, p value = 5.5e−07) (Fig. 1). Analysis of the
depth of coverage in the targeted SOX17 region indicated
nearly 100% of gnomAD samples and a slightly lower per-
centage of PAH-CHD samples attained read depths of at
least 10 (Additional file 1: Figure S2), excluding the possi-
bility that the association is driven by coverage difference
between cases and population data. No other genes
reached the threshold for genome-wide significance. The
top associations with a Benjamini-Hochberg FDR < 1.0 are
listed in Fig. 1b. Notably, three of these genes (BZW2,
FTSJ3, BAZ1B) encode putative SOX17 downstream tar-
gets [38] and two have been implicated in CHD (BAZ1B
[39]) or cardiac defects associated with syndromic intellec-
tual ability (THOC3 [40]). Similar results were obtained
using a smaller cohort of European controls with
individual-level data, called and annotated together with the
PAH-CHD cases (Additional file 1: Figure S3). Based on the
different frequencies between cases and population controls,
we estimate that rare deleterious variants in SOX17 contrib-
ute to about 3.2% of European PAH-CHD patients.
We then searched for SOX17 variants in the
non-European cases in the PAH-CHD cohort, and an add-
itional cohort of 413 idiopathic and familial PAH patients
without CHD (IPAH/HPAH) [41]. We identified two
additional rare LGD and three additional rare D-mis vari-
ants in the PAH-CHD cohort, and one additional rare
LGD (Table 2) and two rare D-mis variants in the IPAH/
HPAH cohort. Variant c.C398T:p.133L, from a European
Table 1 PAH-CHD patient population
Pediatric Adult
Male, n (%) 53 (36.8) 24 (21.4)
Female, n (%) 91 (63.2) 88 (78.6)
Total, n (%) 144 (56.3) 112 (43.7)
Female-to-male ratio 1.7:1 3.7:1a
Ancestry, n (%)
East Asian 7 (4.9) 7 (6.3)
Hispanic 30 (20.8) 27 (24.1)
African 13 (9) 6 (5.4)
South Asian 10 (6.9) 7 (6.3)
European 81 (56.3) 63 (56.3)
Unknown 3 (2.1) 2 (1.8)
Primary cardiac defect, %
Atrial septal defect (ASD) 33.8 55.7
Ventricular septal defect (VSD) 22.5 17.7
ASD + VSD 13.8 7.6
Atrioventricular canal defect 7.5 6.3
Tetralogy of Fallot 5.6 1.3
Transposition of the great vessels 3.8 3.8
Hypoplastic left heart syndrome 1.3 0
Coarctation of the artery 0.6 0
Other/complex 11.3 7.6
aFisher’s exact test, p= 0.009, indicating a higher female-to-male ratio in adult-onset
cases compared to pediatric-onset cases
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patient, was not included in the initial association analysis
due to in silico quality control failure but was later confirmed
by Sanger sequencing. Frameshift variant c.489_510del/
p.Q163fs was observed in three unrelated patients of
European or Hispanic ancestry. Closer examination of the se-
quence revealed a 10-bp repeat, once at the start of the dele-
tion and once just downstream (data not shown), suggesting
that a replication error may explain the recurrence. Among
these three c.489_510del/p.Q163fs mutations, one was a de
novo variant and another inherited from an asymptomatic
parent (Table 2). Five of the six missense mutations occur
within a highly conserved DNA-binding HMG-box domain
(Fig. 2a). Three-dimensional modeling indicates that three of
these mutations (M76V, N95S, W106L) localize within the
DNA binding pocket (Fig. 2b). Comparative sequence
analysis shows that all six of the missense variants are in sites
highly conserved between species, including vertebrates and
invertebrates (Fig. 2c).
We hypothesized that deleterious variants in SOX17
confer PAH-CHD risk through dysregulation of SOX17 tar-
get genes and some of these genes may contribute to
PAH-CHD risk directly, independent of SOX17. Therefore,
we tested for enrichment of rare variants in 1947 putative
SOX17 target genes identified by genome-wide ChIP-X
experiments [38] in European cases compared to NFE gno-
mAD WGS subjects. We observed a moderate but signifi-
cant enrichment of rare missense variants (enrichment rate
= 1.16, p value = 3.4e−4) (Additional file 1: Table S5). Since
there are 618 rare missense variants in these genes in 143




PAH-CHD     
cases (n=143)
gnomAD WGS  
(n=7509) p-value FDR pLI mis-Z
LGD, D-mis (%) LGD, D-mis (%)
SOX17 4, 1 (3.3) 0, 5 (0.07) 5.49E-07 0.01 0.87 3.25
BZW2 0, 3 0, 1 2.63E-05 0.16 1 1.69
SIRT3 1, 2 0, 1 2.63E-05 0.16 2.70E-05 0.82
KLHDC9 0,2 0,0 3.54E-04 0.67 5.37E-06 3.21
THOC6 2,0 0,0 3.54E-04 0.67 2.19E-03 -0.53
KIFC1 2,0 0,0 3.54E-04 0.67 0.02 1.73
FTSJ3 2,0 0,0 3.54E-04 0.67 0.48 -0.64
PIGW 2,0 0,0 3.54E-04 0.67 5.93E-07 -1.12
PUSL1 1,1 0,0 3.54E-04 0.67 6.59E-12 -0.64
BAZ1B 1,1 0,0 3.54E-04 0.67 1 3.80
ALG1 0,3 3,5 9.81E-04 1.00 9.22E-10 -0.29
SOX17





















Fig. 1 Significant association of SOX17 with PAH-CHD. a Quantile-quantile plot showing results of test of rare variant association in 17,701 genes,
using 143 cases of European ancestry and 7509 gnomAD whole genome sequencing subjects of non-Finnish European ancestry. The association
of SOX17 is genome-wide significant following Bonferroni correction for multiple testing. b Table of all genes with p value < 0.001 in the
association tests. False discovery rate (FDR) was estimated using Benjamini-Hochberg procedure. LGD, likely gene-disrupting; D-mis, damaging
missense defined as REVEL score > 0.5
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of rare variants in SOX17-regulated genes may contribute to
PAH-CHD risk. Using publicly available gene expression data
for developing heart [17] and adult pulmonary artery endo-
thelial cells (ENCODE RNA-seq data, ENCBS024RNA), we
found that the majority of the SOX17 target genes with rare
deleterious variants are expressed in one or both of these
tissue/cell types, with 28% (42/149) having top quartile ex-
pression in both tissue/cell types (Additional file 1: Table S6
and Fig. S4a). We assessed the statistical significance of this
expression pattern by building a background distribution
with randomly selected sets of 149 genes that carry at least
one rare LGD or D-mis variant in cases and counted the
number of genes with top quartile ranked expression in both
tissues. Based on 100,000 simulations, the number of ob-
served genes in the top quartile of developing heart and
PAEC expression in the SOX17 targets (42 out of 149) is
significantly larger than expectation by chance (p ≤ 10–5)
(Additional file 1: Figure S4b), supporting functional
relevance of these SOX17 target genes. Pathway enrich-
ment analysis using Reactome 2016 [42, 43] through
Enrichr (amp.pharm.mssm.edu/Enrichr/enrich) showed
that the SOX17 target genes with deleterious variants are
over-represented (FDR-adjusted p value < 0.05) in (1) de-
velopmental processes, (2) transmembrane transport of
small molecules and ion homeostasis, and (3) extracellular
matrix interactions (Additional file 1: Table S7).
Contribution of de novo mutations to PAH-CHD
We have previously reported an enrichment of de novo
predicted deleterious variants in a CHD cohort ascertained
without considering PAH [17, 18]. We tested for a role of
de novo mutations in PAH-CHD in 60 cases with WES data
of biological parents (“trios”). The complete list of 60 rare
de novo variants is provided in Additional file 1: Table S8.
As mentioned previously, three de novo variants were iden-
tified in PAH risk gene TBX4 and one variant each in CHD
risk genes NOTCH1 and PTPN11. However, testing for
enrichment of all rare de novo variants in PAH-CHD trio
probands compared to an estimated background mutation
rate indicated no overall enrichment, likely due to the small
sample size.
Discussion
Exome sequencing in our cohort of 256 PAH-CHD pa-
tients indicated that the genetic contribution of known/
candidate risk genes for PAH or CHD alone is minimal.
An unbiased, gene-based association analysis of rare dele-
terious variants identified SOX17 as a novel PAH-CHD
candidate risk gene, explaining up to 3.2% of cases. A re-
cent study of 1038 PAH cases (not including PAH-CHD)
also found an association of SOX17 with IPAH but with a
smaller effect size (relative risk ~ 2.9) [44]. The observed
frequency of rare variants was ~ 0.9% of PAH cases [44],
similar to our observation of SOX17 variants in ~ 0.7% of
IPAH/HPAH patients without CHD. Of note, no rare
deleterious SOX17 variants were identified in a recently
published cohort of 1200 patients with CHD [18].
Additionally, we observed an enrichment of rare variants
in putative target genes of SOX17. There was no
Table 2 Rare deleterious SOX17 variants identified in 258 PAH-CHD and 413 IPAH/HPAH samples














JM0016 M 5 PAH-CHD ASD European 2 c.C398T p.P133L Paternal – 32.0 0.91
JM0025 M 7 months PAH-CHD VSD European 2 c.489_510del p.Q163fs De novo – 33 N/A
JM1277 F 30 PAH-CHD ASD Asian 2 c.1203delC p.D401fs Unknown – 24.1 N/A
JM1417 F 3 PAH-CHD ASD European 2 c.489_510del p.Q163fs Paternal or
de novo
– 33 N/A
JM174 F 14 PAH-CHD ASD European 2 c.344delG p.R115fs Maternal – 35 N/A
JM654 M 1 PAH-CHD PDA Hispanic 1 c.A284G p.N95S Unknown – 24.7 0.93
JM673 M 34 PAH-CHD ASD European 2 c.C388T p.Q130X Unknown – 39.0 N/A
JM887 F 3 PAH-CHD PDA European 1 c.A226G p.M76V Unknown – 28.7 0.97




Hispanic 2 c.C664G p.P222A Unknown – 26.1 0.57
SPH1070EW5480 F 38 PAH-CHD Unknown Hispanic 2 c.A392G p.D131G Unknown – 22.4 0.89
SPH831KB5173 F 32 IPAH N/A European 2 c.G317T p.W106L Unknown – 28.4 0.9
JM1363 F 5 IPAH N/A Hispanic 2 c.489_510del p.Q163fs Maternal – 33 N/A
FPPH126-01 M 3 HPAH N/A European 1 c.72_76del p.M24fs Unknown – 33 N/A
aASD, atrial septal defect; PDA, patent ductus arteriosus; VSD, ventricular septal defect; AV, atrioventricular
bSOX17 variants identified from transcript NM_022454
cRare, deleterious variants defined as gnomAD AF < 0.01% and REVEL > 0.5
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enrichment of de novo mutations in this cohort, possibly
due to the relatively small number of available trios.
SOX17 is a member of the conserved SOX family of
transcription factors widely expressed in development,
and the subgroup of SOXF genes (including SOX7,
SOX17, and SOX18) participate in vasculogenesis and re-
modeling [45]. In the embryonic vasculature, SOX17 is
selectively expressed in arterial endothelial cells [46–48].
Early studies of Sox17 knock-out mice did not find obvi-
ous abnormalities in embryonic vasculature [49, 50], at
least partially explained by functional redundancy and
compensatory roles of Sox17 and Sox18 [50, 51]. Subse-
quent genetic studies revealed that gene compensation
and phenotypic effects were dependent on strain back-
ground [52]. Recent endothelial-specific inactivation of
Sox17 in murine embryo or postnatal retina led to impaired
arterial specification and embryonic death or arterial-venous
malformations, respectively [46]. SOX17 has also been asso-
ciated with intracranial aneurysms in genome-wide
association studies [53–55], and endothelial-specific Sox17
deficiency was subsequently shown to induce intracranial
aneurysm pathology in an angiotensin II infusion mouse
model [56]. Finally, conditional deletion of Sox17 in mesen-
chymal progenitor cells demonstrated that SOX17 is re-
quired for normal pulmonary vasculature morphogenesis in
utero and deficiency results in postnatal cardiac defects [57].
Cardiogenesis occurs in a highly conserved and regu-
lated manner in the developing embryo [58]. Precise
temporal and spatial control of gene expression is con-
trolled by master transcription factors such as GATA4,
MEF2C, TBX5, and NKX2–5 [59], In addition, signaling

































Human N A FMVWA D L H N A E L GK SWK A L QHMQD H P N Y K L P T P D T S
Chimp N A FMVWA D L H N A E L GK SWK A L QHMQD H P N Y K L P T P D T S
Mouse N A FMVWA D L H N A E L GK SWK A L QHMQD H P N Y K L P T P D T S
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Elephant N A FMVWA D L H N A E L GK SWK A L QHMQD H P N Y K L P T P D T S
Chicken N A FMVWA D L H N A V L GK SWK A L QHMQD H P N Y K L P T P D P S
X_tropicalis N A FMVWA D L H N A E L GK SWK A L QHMQD H P N Y K L P T P E S S
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Zebrafish N A FMVWA D L H N A V L GQSWK A L QH L QD H P N Y K L P T P E M S
P222AQ130X,D131G,P133LM76V N95S W106L
Fig. 2 Rare deleterious variants in SOX17. a Linear schematic of the SOX17 encoded protein and location of genetic variants identified by WES.
LGD variants are in black, D-mis variants in red. b Three-dimensional structure of the SOX17 HMG box domain, comprised of three alpha-helices,
bound to the minor groove of DNA (Protein Data Bank 3F27). Localization of the five patient D-mis variants (red) indicates that three reside
within the DNA binding pocket. c Multiple sequence alignment indicating a high degree of sequence conservation across species at the
locations of SOX17 missense variants
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β-catenin [60, 61] and NOTCH [62] signaling cascades,
drive cardiac morphogenesis and differentiation. SOX17
is a direct transcriptional target of GATA4, giving rise to
SOX17-positive endoderm from embryonic stem cells
[63] and the two proteins co-localize in the primitive
endoderm [64, 65]. SOX17 induction inhibits WNT/
β-catenin signaling by direct protein interaction with
β-catenin through a carboxyl terminal domain of SOX17
required for transactivation of target genes [66, 67].
NOTCH1 has recently been shown to be a direct tran-
scriptional target of SOX17 in early arterial development
[68]. Thus, it is possible that impaired functional interac-
tions between these molecules during embryogenesis
could provide an underlying mechanism for the develop-
ment of CHD in some PAH-CHD patients.
SOX17 is a highly constrained gene depleted of LGD and
missense variants in a large population data set (ExAC pLI
= 0.87, missense Z-score = 3.25) [26]. About half of the ob-
served rare, deleterious variants in cases are LGD variants,
and most of the missense variants are located in a conserved
HMG box domain. The HMG box is a 79-amino acid do-
main that binds in a sequence-specific manner within the
minor groove of DNA causing bending and facilitating as-
sembly of nucleoprotein complexes [45]. Localization of the
five HMG box missense variants within a three-dimensional
model of the protein domain interacting with DNA indi-
cated that three of the patient missense mutations (M76V,
N95S, W106L) localize to the DNA binding pocket (Fig. 2b).
Previously reported site-directed mutagenesis studies indi-
cate that similar point mutations within this region (M76A,
G103R) can impair both direct DNA binding [69] and com-
plex nucleoprotein interactions, including SOX17/β-catenin
protein complexes, at target gene promoters [70, 71]. This
suggests that haploinsufficiency with loss of function alleles
is the likely mechanism of SOX17 risk in PAH-CHD.
Some variants in SOX17 downstream target genes may
be predicted to mimic some of the consequences of SOX17
loss of function mutations or haploinsufficiency. We identi-
fied 163 rare deleterious variants (131 D-mis and 32 LGD)
in 149 putative target genes. Using published gene expres-
sion data, we found that most of these genes are expressed
in developing heart and/or pulmonary artery endothelial
cells, with significant enrichment of top quartile expression
in both tissue/cell types compared to randomly selected
sets of genes carrying deleterious variants in European
PAH-CHD cases. Additionally, we showed that these target
genes are overrepresented in pathways related to develop-
mental biology, ion transport/homeostasis, and extracellular
matrix interactions. A wide range of transmembrane small
molecule transporters/channels/pumps are expressed in de-
veloping heart and pulmonary vasculature, and some have
been shown to be differentially expressed in lung tissue
from PAH patients compared to non-disease controls or
PH with interstitial fibrosis [72]. As key regulators of
vascular tone, some of these molecules function as targets
of vasodilatory pharmacotherapy [73]. We recently identi-
fied the potassium channel gene, KCNK3, as a risk gene for
PAH using exome sequencing [74]. Extracellular matrix
proteins, including laminins, play key roles in embryonic
development of both pulmonary vasculature and heart [75].
Thus, it is likely that mutations in SOX17, and possibly
downstream target genes, may increase risk for PAH-CHD
via multiple pathways.
The striking clinical finding was that nine out of 13 pa-
tients had pediatric-onset disease. The mean age of PAH
onset for all patients with rare SOX17 variants was
14.2 years. Most of the congenital heart defects were simple
(i.e., atrial septal defect, ventricular septal defect, or patent
ductus arteriosus). However, most of the patients had
severe PAH with systemic or supersystemic resting pul-
monary arterial pressures, right ventricular hypertrophy
with diminished right ventricular function, and requiring
chronic intravenous vasodilator treatment. Severe PAH was
observed in all patients carrying variants in the HMG-box
domain or the recurrent c.489_510del/ p.Q163fs variant.
Conclusions
Together, these data strongly implicate SOX17 as a new
risk gene contributing to ~ 3% of PAH-CHD cases and
suggest that rare variants in genes regulated by SOX17
also contribute to PAH-CHD. Expansion of the number
of PAH-CHD patients assessed and characterization of
the clinical phenotypes will be important to confirm the
role of SOX17 in PAH-CHD and IPAH, and more pre-
cisely estimate the contribution of genes regulated by
SOX17 and de novo mutations.
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